Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Ohio Med Spas: Peptide Do's and Do Not's

Client Alert
April 29, 2026

Recent Ohio Board of Pharmacy (“BOP”) guidance has highlighted compliance considerations surrounding the use of peptides in med spas.  Owners and operators of med spas will want to keep these considerations in mind as the use of peptides, especially GLP-1 medications, expands.  

Certain peptide drugs are FDA approved medications and can be used in med spas. However, not every peptide-based drug is created equal or is approval by the FDA. According to BOP guidance, some peptides, such as Retatrutide, are not currently FDA approved.[1] In addition, many peptide-based drugs, such as Semaglutide or BPC-157 peptides, cannot currently be compounded.[2]

The BOP conducts regular inspections of med spas and has revoked or suspended several med-spa’s TDDD licenses for violations surrounding the use of peptides. The most common violations are purchasing medication from an unlicensed seller, purchasing and utilizing medication marked “for research purposes only,” purchasing non-FDA approved medication, and obtaining foreign sourced medication.   

When determining which peptides your med-spa can utilize, it is important to keep the following considerations in mind:

  • Only use peptides that are FDA approved.
  • Do not purchase peptides from unlicensed sellers.
  • Do not use peptides labeled “for research purposes only.”
  • Ensure compliance with compounding requirements, including not making prohibited copies of peptides.
  • Properly store any peptides prior to their use.

If you have questions regarding BOP compliance or how using peptides may impact your practice, please contact BMD Member Jeana Singleton at jmsingleton@bmdllc.com or 330-253-2001.     

[1] Compounding of Glucagon-like Peptide-1 Drug Products (GLP-1) in Ohio, Ohio Board of Pharmacy, last accessed April 23, 2026.

[1] Ten Common Prescriber Clinic and Medical Spa Violations, Ohio Board of Pharmacy, last accessed April 23, 2026. See also, Compounding of Glucagon-like Peptide-1 Drug Products (GLP-1) in Ohio, Ohio Board of Pharmacy, last accessed April 23, 2026.

HealthcareHealth LawOhio State Board of PharmacyMedSpaJeana Singleton
Client Alert

CMS and Ohio Ramp Up Fraud Enforcement in Home Health and Hospice

May 15, 2026CMS and Ohio have launched sweeping new fraud prevention initiatives targeting home health and hospice providers, signaling a period of heightened scrutiny for enrollment, billing, documentation, and EVV compliance. While aimed at combating fraud, these measures also create significant operational and due process risks for compliant agencies, making proactive compliance programs, auditing, and governance more important than ever.Client Alert

MYTH BUSTER: Can a New Chiropractor Bill Under An Established Chiropractor’s NPI?

May 14, 2026Many chiropractic practices mistakenly believe a newly hired chiropractor can bill under an established chiropractor’s NPI while waiting for credentialing approval. In most cases, this is not permitted. Claims should be submitted under the NPI of the chiropractor who actually rendered the service to avoid compliance risks, including potential False Claims Act exposure. This article outlines key billing rules, common exceptions, and practical compliance tips for chiropractic practices.Client Alert

RNs and APRNs Take Note: Ohio Board of Nursing Mandates a New CE Reporting Period

April 29, 2026Ohio’s Board of Nursing has updated the continuing education reporting period for RNs and APRNs. Beginning March 26, 2026, CE credits must be completed between July 1 and June 30 of odd-numbered years, replacing the previous November to October timeframe.Client Alert

Substance Use Disorder Providers: 42 CFR Part 2 Now Enforceable

April 15, 2026Updates to 42 CFR Part 2 are now enforceable, bringing significant changes to how substance use disorder (SUD) records are handled. The Final Rule aligns Part 2 more closely with HIPAA, introduces updated penalties, allows a single patient consent for treatment, payment, and operations, and adds new requirements for Notices of Privacy Practices. It also creates a formal definition of SUD counseling notes and imposes strict consent requirements for their use and disclosure. Providers should review and update policies to ensure compliance.Client Alert

AAA Introduces AI-Assisted Arbitrator for Certain Disputes

April 7, 2026The American Arbitration Association has introduced an AI-assisted arbitration platform designed to streamline certain document-based disputes. While a human arbitrator still makes the final decision, the technology can improve efficiency, reduce costs, and accelerate case resolution. Companies should weigh these benefits against considerations such as transparency, risk, and contractual requirements before adopting AI-assisted arbitration.
Older posts
Newer posts